Conditional sentence

Arma Biosciences Announces Efforts Towards a New Biomarker Monitoring System for Virtual Healthcare

Retrieved on: 
Wednesday, September 28, 2022
Analog Devices, ICS, Biomarker, Conditional sentence, Health, Patient, Technology, Data collection, DSP, Arma, Medicine, Marketing, Multimedia, Disease, Medical imaging

TORONTO, Sept. 28, 2022 /PRNewswire/ - Arma Biosciences today announced a joint development effort with Analog Devices, Inc. regarding a new technology platform that is expected to enable remote biomarker monitoring for enhanced virtual healthcare delivery.

Key Points: 
  • TORONTO, Sept. 28, 2022 /PRNewswire/ - Arma Biosciences today announced a joint development effort with Analog Devices, Inc. regarding a new technology platform that is expected to enable remote biomarker monitoring for enhanced virtual healthcare delivery.
  • Virtual healthcare is now a cornerstone of clinical practice that is changing how medicine is delivered to patients.
  • Arma Biosciences is commercializing a new molecular detection technology that possesses unprecedented simplicity for the development of user-friendly devices for biomarker monitoring.
  • "Arma and Analog Devices are collaborating on a new testing system leveraging the new sensing approach and core microelectronic technologies.

Magnetic Resonance Imaging Market to Surpass Value of US$ 10.6 Bn by 2031: TMR Study

Retrieved on: 
Wednesday, September 28, 2022
TMR, Adoption, Incidence, Ageing, Prevalence, Hitachi, Elective surgery, Neoplasm, MRI, Population, Embrace Neonatal MRI System, Growth, Spine, Hand, Patient, Investment, Claustrophobia, Pediatrics, Google Images, Spinal cord injury, Diagnosis, Magnetic resonance imaging, US, GE Healthcare, Lists of countries and territories, Conditional sentence, Medical imaging, Medtech

The analysts opine that development of MRI systems that are suitable for claustrophobic and obese patients presents value-grab opportunities for medtech companies in magnetic resonance imaging market.

Key Points: 
  • The analysts opine that development of MRI systems that are suitable for claustrophobic and obese patients presents value-grab opportunities for medtech companies in magnetic resonance imaging market.
  • Rise in demand for magnetic resonance imaging (MRI) procedures in elderly population is a key market driver, observed the TMR study.
  • Continuous research and development of imaging equipment with emphasis on patient comfort has extended horizon for investments in the magnetic resonance imaging market.
  • Medtech companies in magnetic resonance imaging market are leaning on leveraging the synergies of strategic partnerships with diagnostic imaging services providers.

Magnetic Resonance Imaging Market to Surpass Value of US$ 10.6 Bn by 2031: TMR Study

Retrieved on: 
Wednesday, September 28, 2022
TMR, Adoption, Incidence, Ageing, Prevalence, Hitachi, Elective surgery, Neoplasm, MRI, Population, Embrace Neonatal MRI System, Growth, Spine, Hand, Patient, Investment, Claustrophobia, Pediatrics, Google Images, Spinal cord injury, Diagnosis, Magnetic resonance imaging, US, GE Healthcare, Lists of countries and territories, Conditional sentence, Medical imaging, Medtech

The analysts opine that development of MRI systems that are suitable for claustrophobic and obese patients presents value-grab opportunities for medtech companies in magnetic resonance imaging market.

Key Points: 
  • The analysts opine that development of MRI systems that are suitable for claustrophobic and obese patients presents value-grab opportunities for medtech companies in magnetic resonance imaging market.
  • Rise in demand for magnetic resonance imaging (MRI) procedures in elderly population is a key market driver, observed the TMR study.
  • Continuous research and development of imaging equipment with emphasis on patient comfort has extended horizon for investments in the magnetic resonance imaging market.
  • Medtech companies in magnetic resonance imaging market are leaning on leveraging the synergies of strategic partnerships with diagnostic imaging services providers.

Global Protein Hydrolysate Market Report to 2030 - Featuring Abbott, Nestle, AMCO Proteins and Healy Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 28, 2022
Food, Beverage, Retail, Arla Foods, Inflammatory bowel disease, Growth, Glucose, Hydrolysis, National Academies of Sciences, Engineering, and Medicine, Cancer, Nutrient, Protein, Exercise, National academy, Phosphorus, Food, Organic acid, Calcium, Dietary supplement, Muscle, Human, IBD, R, Awareness, Glycogen, Drink, Conditional sentence, CAGR, Engineering, Medicine

The rising awareness about the health benefits of protein hydrolysates is a major factor driving the growth of the market.

Key Points: 
  • The rising awareness about the health benefits of protein hydrolysates is a major factor driving the growth of the market.
  • Protein hydrolysates are widely used as dietary supplements due to their ability to provide essential nutrients and improve muscle functions.
  • The rising awareness about the health benefits of protein hydrolysates is a major factor driving the growth of the market in North America.
  • For this report, the author has segmented the global protein hydrolysate market based on product, form, application, method, and region:

NACDS Brings “Face of Neighborhood Healthcare” to White House Conference on Hunger, Nutrition, and Health

Retrieved on: 
Wednesday, September 28, 2022
COVID-19, Policy, Trust, Equitable, WIC, Conditional sentence, Nutrition, Special, Prescription, Pharmacy, Obesity, National Strategy for Trusted Identities in Cyberspace, Hypertension, Industry, Diabetes, Health equity, White House Conference on Food, Nutrition, and Health, Patient, Partnership, Nutrition and Health, Supplemental Nutrition Assistance Program, COVID-19 policy of the Joe Biden administration, Joe Biden, SNAP, Pharmacist, Goal, Solution, AFAC, Food, White House, Conference, Association, Medicine, Supermarket, Awareness, GLOBE, National Association, Good Neighbor Pharmacy, White House conference, Pharmaceutical industry, Health insurance, Hunger, Woman, Health

NACDS President & CEO Steven C. Anderson and member company representatives are participating first-hand in the White House Conference.

Key Points: 
  • NACDS President & CEO Steven C. Anderson and member company representatives are participating first-hand in the White House Conference.
  • The commitments that NACDS made today in collaboration with the White House Conference were highlighted in a White House Fact sheet during the Conference.
  • NACDS President and CEO Steven C. Anderson said, We are proud to support the White House Conference on Hunger, Nutrition and Health.
  • NACDS will continue to advance the recommendations that the Association issued to help inform the White House Conference.

Global Medical Device Security Market Report to 2031 - by Component, Security Type, Device Type, Deployment Mode, End User and Region - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 28, 2022
Medical Devices, Health, Conditional sentence, Adoption, Research, Population, Data collection, Compliance, Growth, Ageing, Medical device

The "Global Medical Device Security Market 2021-2031: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Medical Device Security Market 2021-2031: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.
  • The report is based on a comprehensive research of the entire global medical device security market and all its sub-segments through extensively detailed classifications.
  • Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain.
  • The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year.

Cleara Biotech Raises $2.5 Million in Seed Financing to Advance FOXO4-Therapeutics Pipeline for Treating Cancer and Chronic Diseases

Retrieved on: 
Wednesday, September 28, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Apoptosis, Precision medicine, Human, MTD, Organoid, Homeostasis, Biomarker, UMCU, Director, Company, Mouse, University Medical Center, FOXO4, Cell, Board of directors, Drug development, Board, University Medical Center Utrecht, Pharmacokinetics, Peptide, Conditional sentence, Pharmaceutical industry, Medical imaging, EU

The proceeds will be used to progress Clearas compounds toward clinical development and further build the Companys developmental pipeline and management team.

Key Points: 
  • The proceeds will be used to progress Clearas compounds toward clinical development and further build the Companys developmental pipeline and management team.
  • Cleara has optimized two lead developmental candidates, CL04177 and CL04183, that can eliminate scarred cancer cells found in several late-stage cancers and chronic diseases in humans.
  • Clearas lead program is designed to generate disruptive, innovative and proprietary technology against scarred cellular senescence against late-stage cancer and chronic diseases.
  • Cleara is a platform-based company that utilizes knowledge against senescence subtypes and develops compounds to eliminate these in respective diseases.

Real World Evidence of Cala TAPS Therapy Further Supports Long-Term Safety and Efficacy of its Treatment for Essential Tremor

Retrieved on: 
Tuesday, September 27, 2022
Research, Medical Devices, Clinical Trials, Health Technology, Biotechnology, Health, Pharmaceutical, General Health, Science, Contraindication, Pain disorder, Time, Degenerative disease, ET, Journal, FDA, Prevalence, Sale, Lists of diseases, Eating, Psychiatry, Conditional sentence, Hospital, San Francisco Bay Area, TAPS, Parkinson's disease, Essential tremor, Health, Hypertension, Diabetes, Patient, Movement disorders, CEO, Technology, Mischer Neuroscience Institute, Standard of care, Cardiology, Anxiety, Drinking, Neurology, Silicon, Structured Product Labeling, List of Veterans Affairs medical facilities, Depression, Medical device, Pharmaceutical industry, Residential care, Tremor

TAPS reduced tremor power by 71% (geometric mean), confirming previous findings from the PROSPECT clinical study1.

Key Points: 
  • TAPS reduced tremor power by 71% (geometric mean), confirming previous findings from the PROSPECT clinical study1.
  • Of the patients who were on tremor medication prior to starting Cala TAPS therapy, 24% reduced their tremor medication and 14% discontinued medication use.
  • The evidence, coupled with self-reported quality of life improvement and patient preference for TAPS, reinforce that TAPS is a valuable treatment option for patients with ET.
  • Cala TAPS therapy, delivered by the Cala Trio device, is the only FDA-cleared, clinically validated bioelectronic therapy for hand tremor relief for patients with essential tremor.

Global Clinical Laboratory Services Market Report 2022: Rising Incidences of Chronic and Infectious Diseases Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 27, 2022
Health, General Health, TB, Laboratory, National Accreditation Board for Testing and Calibration Laboratories, Incidence, COVID-19, NABL, Prevalence, Biomarker, ID, Tuberculosis, Population, Abbott, COVID, USD, Cancer, Canadian Cancer Society, Diagnosis, American Cancer Society Cancer Action Network, Method, Malaysian Qualifications Agency, Research, COVID-19 testing, Awareness, Education, Infection, Conditional sentence, CAGR, Pharmaceutical industry, Dietary supplement, Growth

The "Clinical Laboratory Services Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Clinical Laboratory Services Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.
  • The global clinical laboratory services market is estimated to be USD 2,26,812.3 million in 2021.
  • The market is primarily driven by the rising incidences of chronic and infectious diseases and the increasing demand for accurate and early disease diagnosis techniques.
  • The presence of key market players in the country, new product innovations, and launches are further expected to complement the growth of the clinical laboratory services market in the country.

Penn Medicine, Independence Blue Cross, and Tandigm Health Partner to Expand Value-Based Care

Retrieved on: 
Tuesday, September 27, 2022
Adoption, Center, Medicare, Sale, Population Health Management, Organization, University of Pennsylvania Health System, Independence Blue Cross, Penn Medicine Princeton Medical Center, Diabetes, Patient, Medicare Advantage, Physician, CEO, Centers for Medicare & Medicaid Services, University, Conditional sentence, Hospital, Pharmaceutical industry, Health insurance, Humana, Independence

PHILADELPHIA, Sept. 27, 2022 /PRNewswire/ -- Independence Blue Cross (Independence) and Penn Medicine today announce a plan to deepen their longstanding collaborations to transform healthcare in the Philadelphia region. The centerpiece of this expanding relationship is Independence's sale of a minority equity stake in its subsidiary, Tandigm Health, to Penn Medicine, which will allow more patients to continue seeing their trusted primary care providers close to home while offering new, innovative pathways to Penn Medicine's specialty care and other services. Together, the organizations will join forces in new ways to improve patient outcomes and drive more cost-efficient care, while also increasing provider satisfaction.

Key Points: 
  • The agreement, which officially launches on January 1, 2023, also contains a long-term commitment from Penn Medicine to work with Tandigm for all primary care value-based programs across all payors.
  • Independence and Penn Medicine have collaborated extensively to accelerate the adoption of value-based care.
  • "Tandigm is honored to earn the trust of Independence, Penn Medicine, and the Tandigm network of outstanding physicians," said Frank Ingari, CEO of Tandigm.
  • Moving forward in the new arrangement, Tandigm primary care providers may be able to expand their impact through facilitated access to Penn Medicine resources such as specialty care, advanced home care services, and virtual off-hours coverage for patients in need outside of office hours.